共 162 条
Conformational properties of HIV-1 gp120/V3 immunogenic domains
被引:14
作者:
Galanakis, PA
Spyroulias, GA
[1
]
Rizos, A
Samolis, P
Krambovitis, E
机构:
[1] Univ Patras, Sch Hlth Sci, Dept Pharm, GR-26504 Patras, Greece
[2] Univ Crete, Dept Chem, GR-71409 Iraklion, Greece
[3] Fdn Res & Technol Hellas, IESL, GR-71409 Iraklion, Greece
[4] Fdn Res & Technol Hellas, Inst Mol Biol, Dept Appl Immunol, GR-71409 Iraklion, Greece
[5] Univ Thessaloniki, Dept Vet Med, Kardhitsa, Greece
关键词:
AIDS;
HIV-1;
gp120;
V3 hypervariable loop;
CCR5/CXCR4;
co-receptors;
HIV inhibitors;
X-ray crystallography and NMR spectroscopy;
D O I:
10.2174/0929867054038982
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Infection of target host cells by the human immunodeficiency virus-1(HIV-1) is a multi-step process involving a series of conformational changes in the viral gp120 and gp41 proteins. Gp120 binding to the main cell receptor, CD4, on the surface of cells expressing this molecule, and interaction with the cell chemokine receptors CCR5 and CXCR4, are among the key events for HIV-1 infection. These steps are crucial for the virus and offer potential therapeutic targets. For this reason, understanding the structure and the physicochernical characteristics of the gp120 in relation to these interactions has drawn much attention. This review article focuses on the biologically important V3 region of the gp120 and summarizes the functional role, the sequence variation and the conformational features of V3 peptides, which are important for co-receptor selectivity, specificity and interaction. Synthetic V3 peptides have been extensively studied by NMR spectroscopy and X-ray crystallography, in solution or in solid state, in their free or bound form, and valuable information was generated with the aim to be exploited in the design of new, effective inhibitors of HIV-1 infection. The features of the potential gp120 interacting sites on the two chemokine co-receptors, CCR5 and CXCR4, are also discussed, and co-receptor blocking molecules under clinical trial are also reported.
引用
收藏
页码:1551 / 1568
页数:18
相关论文